Why the study?
Data on the management and clinical outcomes of patients with myocarditis-associated cardiogenic shock were limited.
Does myocarditis-associated cardiogenic shock increase in-hospital death compared to non-myocarditis cardiogenic shock in adults?
Does myocarditis-associated cardiogenic shock increase in-hospital death compared to non-myocarditis cardiogenic shock in adults?
Myocarditis-associated cardiogenic shock represents a critically ill population with a higher adjusted in-hospital mortality rate compared to other causes of cardiogenic shock.
Answers are grounded in this paper and cite their sources.
May signal need for heightened vigilance in myocarditis-associated cardiogenic shock; leaves open etiology-specific management.
BACKGROUND: There are limited data on the management of myocarditis-associated cardiogenic shock. The aim of this study was to assess the clinical outcomes of patients with myocarditis-associated cardiogenic shock. METHODS: In this retrospective study using the Vizient Clinical Data Base, patients aged ≥18 years admitted with cardiogenic shock during 2015 through 2023 across the United States were stratified by myocarditis status. We assessed in-hospital death by augmented inverse probability weighting, accounting for demographics, comorbidities, critical care therapies, and hospital characteristics. CONCLUSIONS: Myocarditis-associated cardiogenic shock is uncommon yet represents a critically ill population with a higher adjusted in-hospital mortality rate. Future work investigating therapies for this unique patient population is warranted.
No takes yet. Share an insight, caveat, or question.
Zarif et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: